The Stock now has a Weekly Volatility of 2.97% and Monthly Volatility of 2.84%.
These analysts also forecasted Growth Estimates for the Current Quarter for TEVA to be -9.6%. The institutional investor held 876,865 shares of the major pharmaceuticals company at the end of 2016Q4, valued at $31.79 million, down from 1.05 million at the end of the previous reported quarter. Analysts giving shares a rating of 1 or 2 would be indicating a Buy. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/05/24/dnb-asset-management-as-acquires-56900-shares-of-teva-pharmaceutical-industries-ltd-teva-updated.html.
MA reduced its stake in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 2.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission.
Among 14 analysts covering The Dow Chemical Company (NYSE:DOW), 8 have Buy rating, 1 Sell and 5 Hold. Teva Pharmaceutical Industries now has an average rating of "Hold" and a consensus target price of $43.91.
TEVA has a 1-year high price of $ 56.44 and 1-year low price of $28.47. The stock has a market cap of $29.44 billion, a P/E ratio of 371.54 and a beta of 0.58. Shares are trading 28.70% above their 50-day moving average, and 57.74% below their 200-day moving average. Bank of America Corp raised Teva Pharmaceutical Industries from a "neutral" rating to a "buy" rating in a research report on Tuesday, January 31st. Stock traders bought 963 put options on the stock. More interesting news about Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) were released by: Investorplace.com and their article: "Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Is a Good Spec Buy" published on March 08, 2017 as well as Benzinga.com's news article titled: "Vetr Issues Strong Buy As Teva Trends Down" with publication date: May 19, 2017. The analysts estimated mean EPS at 1.24 while the high and low EPS estimate stand at 1.37 and 0.92 respectively. The company had revenue of $5.63 billion during the quarter, compared to analyst estimates of $5.69 billion. Earnings per share serves as an indicator of a company's profitability. The firm's revenue for the quarter was up 17.0% on a year-over-year basis. Share performance for the month is now at -11.07%. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of United States & worldwide copyright & trademark laws.
TRADEMARK VIOLATION WARNING: This report was first published by Chaffey Breeze and is owned by of Chaffey Breeze.
The company also recently announced a quarterly dividend, which will be paid on Thursday, June 22nd. Shareholders of record on Monday, June 5th will be given a dividend of $0.34 per share. A rating of 4 or 5 would represent a Sell recommendation. Teva Pharmaceutical Industries's payout ratio is 1,657.38%.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Norges Bank acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at about $495,909,000. Oppenheimer Holdings Inc. set a $43.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a buy rating in a report on Tuesday, February 14th. Finally, Barrow Hanley Mewhinney & Strauss LLC increased its position in shares of Teva Pharmaceutical Industries by 22.1% in the fourth quarter. NEXT Financial Group Inc raised its position in Teva Pharmaceutical Industries by 50.7% in the third quarter. SOL Capital Management CO now owns 34,447 shares of the company's stock valued at $1,585,000 after buying an additional 1,900 shares during the period. TCI Wealth Advisors Inc. raised its position in Teva Pharmaceutical Industries by 69.8% in the third quarter. They are projecting Next Quarter growth of -4.6%. Commerzbank Aktiengesellschaft FI owned about 0.09% of Teva Pharmaceutical Industries worth $29,814,000 at the end of the most recent reporting period. Salem Investment Counselors Inc. now owns 8,332 shares of the company's stock worth $267,000 after buying an additional 32 shares in the last quarter.